Mineralys Therapeutics

Cleveland Clinic-led clinical trial demonstrates lorundrostat, an aldosterone synthase inhibitor, reduced systolic blood pressure by 8 points more than placebo in patients with uncontrolled hypertension.

Mineralys Therapeutics has priced its public offering at $13.50 per share, raising approximately $175 million to fund the clinical development of lorundrostat, its aldosterone synthase inhibitor.

Mineralys Therapeutics' lorundrostat receives FDA clearance for a Phase 2 trial targeting obstructive sleep apnea (OSA) in hypertensive patients.

• Mineralys Therapeutics completed enrollment in the pivotal Advance-HTN trial for uncontrolled or resistant hypertension, with topline data expected in March 2025. • The company also completed enrollment ahead of schedule in the Phase 3 Launch-HTN trial, anticipating topline data in the first half of 2025. • Enrollment is ongoing in the Explore-CKD Phase 2 trial, which is evaluating lorundrostat in patients with hypertension and Stage 2 to 3b chronic kidney disease, with topline data expected in Q2 2025.

• Mineralys Therapeutics completed enrollment in the Launch-HTN trial, a Phase 3 study evaluating lorundrostat for uncontrolled or resistant hypertension, ahead of schedule. • The Launch-HTN trial is a randomized, double-blinded, placebo-controlled study assessing the efficacy and safety of lorundrostat in adult participants on multiple antihypertensive medications. • Topline data from the Launch-HTN trial, which models real-world treatment in the primary care setting, is now expected in mid first half of 2025. • Lorundrostat is a selective aldosterone synthase inhibitor being developed for hypertension and chronic kidney disease, targeting dysregulated aldosterone levels.